Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of oral administration of
orismilast for treatment of mild, moderate, or severe hidradenitis suppurativa (HS) in
adults.